Piracetam 200mg/ml 5 ml, 10 pcs.

Piracetam activates associative processes in the central nervous system, improves mood, memory and mentality in sick and healthy people. It stimulates intellectual activity and integrative activity of the brain, facilitates learning processes, improves connections between hemispheres of the brain and synaptic conduction in the cortex, increases mental performance, stabilizes and restores impaired brain functions (memory, consciousness, speech). Piracetam normalizes the ratio of ADP and ATP (inhibits nucleotide phosphatase and activates adenylate cyclase), increases phospholipase A activity, stimulates bioenergetic and plastic processes in nervous tissue, and accelerates neurotransmitter exchange.

Piracetam increases resistance of brain tissue to toxic influences and hypoxia, increases the synthesis of phospholipids and nuclear RNA, and increases glycolytic processes and glucose utilization in the brain. Piracetam blocks platelet aggregation, improves microcirculation, optimizes the ability of red blood cells to pass through microvessels and the conformational properties of the red blood cell membrane, increases regional blood flow in ischemic brain areas. Piracetam increases EEG beta and alpha activity and decreases delta activity. It reduces vestibular nystagmus. During hypoxia, intoxication, trauma, electroconvulsive effect has a neuroprotective effect.

In connection with antihypoxic action piracetam is effective in complex treatment of myocardial infarction. Anxiolytic and sedative effects of piracetam are absent.

Piracetam is almost completely and quickly absorbed after oral administration. Bioavailability is 100%. When oral administration of 2 g of the drug the maximum concentration in plasma is 40-60 mcg/ml after 30 minutes. Piracetam does not bind to plasma proteins. After 2-8 hours the maximum concentration in the cerebrospinal fluid is reached. Piracetam penetrates all tissues and organs, penetrates through the placental barrier. It is almost not metabolized. It accumulates selectively in cerebral cortex, mainly in parietal, frontal and occipital lobes, basal ganglia and cerebellum. Half-life of piracetam from plasma is 4-5 hours; from cerebrospinal fluid it is 6-8 hours. More than 95% of the drug is excreted unchanged by the kidneys after 30 hours. The elimination half-life is longer in patients with renal insufficiency.

Indications

Acquired dementia, Impaired cerebral circulation, Hangover, Concussion and other brain injuries, Impaired attention and memory, Dizziness, Disorientation, Mental retardation in children, Learning disabilities, Tinnitus, Alcoholism, Stroke after-effects, Headache, Alzheimer’s disease< ulUl>

Active ingredient

Piracetam

Composition

Active substance:

piracetam – 200.0 g

Auxiliary substances:

Sodium acetate – 1 g,

Acetic acid diluted – to pH 5.0-5.8,

Injectable water – up to 1 liter.

How to take, the dosage

The drug is administered intramuscularly or intravenously.

The use of piracetam in adults:

In the treatment of cerebrovascular disorders in the acute phase the drug should be prescribed as early as possible, in a dose of 12 g per day for 2 weeks, and then 4.8-6 g per day.

In cortical myoclonias, treatment begins with a dose of 7.2 g per day; every 3-4 days the dose is increased by 4.8 g per day until a maximum dose of 24 g per day is reached, 2-3 times per day, orally or parenterally. Every 6 months, the dose should be reduced by 1.2 g every 2 days.

In sickle cell anemia, the daily dose is 160 mg/kg, divided into 4 equal portions. During a crisis, up to 300 mg/kg.

In alcoholism – 12 g per day during the manifestation of ethanol “withdrawal” syndrome; maintenance dose – 2.4 g.

In treatment of comatose states, in post-traumatic period the initial dose is 9-12 g per day, maintenance dose – 2.4 g, treatment course is 3 weeks.

Interaction

Piracetam increases the effects of indirect anticoagulants, psychostimulants, central effects of thyroid hormones (anxiety, tremor, sleep disturbance, irritability, confusion).

The severity of extrapyramidal disorders is increased when piracetam is combined with neuroleptics.

Contraindications

Hypersensitivity (including to pyrrolidone derivatives), marked renal insufficiency (with creatinine clearance less than 20 ml/min), hemorrhagic stroke, Huntington’s disease, agitated depression, breastfeeding, pregnancy, age less than 1 year.

Side effects

Nervous system and senses: hyperkinesia, drowsiness, increased irritability, depression, agitation, asthenia, aggressive behavior, dizziness, sleep disturbance, headache, tremor, increased sexuality;

Digestive system: nausea, diarrhea, vomiting, abdominal pain;

Metabolism: weight gain;

Circulatory system: exacerbation of coronary artery disease, arterial hypertension or hypotension;

Skin: hypersensitivity reactions.

Overdose

In case of overdose with piracetam side effects increase.

Treatment: gastric lavage, activated charcoal, symptomatic treatment; there is no specific antidote, hemodialysis is possible (effectiveness is 50-60%).

Similarities

Nootropil, Piracetam, Piracetam bufus, Notrocetam